TG Therapeutics
TGTX
91 hedge funds and large institutions have $101M invested in TG Therapeutics in 2016 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 38 increasing their positions, 15 reducing their positions, and 6 closing their positions.
233% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 6
153% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 15
39.64% more ownership
Funds ownership: 0% → 39.64% (+40%)
18% more funds holding
Funds holding: 77 → 91 (+14)
52% less capital invested
Capital invested by funds: $208M → $101M (-$107M)
93% less call options, than puts
Call options by funds: $57K | Put options by funds: $779K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$905K |
| 2 |
Millennium Management
New York
|
+$855K |
| 3 |
CCI
Columbus Circle Investors
|
+$829K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$664K |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$634K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$21.3M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$15.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.27M |
| 4 |
BM
Bridger Management
New York
|
-$1.66M |
| 5 |
FAM
Fred Alger Management
New York
|
-$542K |
TGTX Hedge Fund Activity: Q4 2016 in Review
91 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q4 2016, worth a combined $101M — down 52% from $208M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new TGTX positions and 6 closed out — a net gain of 14 holders — while 38 added to existing stakes and 15 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $905K. The largest seller was RA Capital Management, cutting an estimated $21.3M.
- 91 institutional investors held TG Therapeutics (TGTX) as of Q4 2016, up from 77 in Q3 2016.
- Funds reported $101M of TG Therapeutics stock for Q4 2016, down 52% quarter-over-quarter.
- 20 funds opened new TG Therapeutics positions in Q4 2016 and 6 closed out, a net change of +14 holders.
- The largest TG Therapeutics buyer in Q4 2016 was BlackRock Fund Advisors, an estimated $905K added.
- The largest TG Therapeutics seller in Q4 2016 was RA Capital Management, an estimated $21.3M sold.
Based on aggregated 13F filings for Q4 2016.